EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy

Laetitia Saccenti, Nicole Varble, Tabea Borde, Andrew S Mikhail, Michael Kassin, Elliot Levy, Sheng Xu, Lindsey A Hazen, Ifechi Ukeh, Cyndi Vasco, Austin G Duffy, Changqing Xie und 4 weitere

La radiologia medica · 2024

DOI: 10.1007/s11547-024-01937-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift La radiologia medica, 2024. Verfasst von Laetitia Saccenti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20…. Hauptthemen laut MEDLINE: Liver Neoplasms, Immune Checkpoint Inhibitors, Tomography, X-Ray Computed, Carcinoma, Hepatocellular. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Société Française de Radiologie, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health Clinical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to assess the feasibility of quantifying morphologic changes in tumors during immunotherapy, as a reflection of response or survival. Methods and materials A retrospective single-center analysis was performed in patients with unresectable liver cancer previously enrolled in clinical trials combining immunotherapy (tremelimumab ± durvalumab) and locoregional treatment (either ablation or transarterial chemoembolization). Conventional response (RECIST 1.1) was assessed at 6-month follow-up. For morphologic assessment, the largest target lesion was manually segmented on axial slices in two dimensions using contrast-enhanced CT. Solidity and circularity of tumors were calculated at baseline, 3-month follow-up, and at 6-months follow-up. Survival analysis was performed.

Results

From the 68 patients enrolled in clinical trials, 28 did not have target lesions separate from lesions treated by locoregional therapies, and 3 had no follow-up imaging. Thirty-seven patients (9 with biliary cancer and 28 with hepatocellular carcinoma) were included. Shape features and shape variation were not correlated with RECIST 1.1 status at 6-month follow-up. However, patients with low solidity tumors at 6-month follow-up showed poorer prognosis compared with patients with high solidity tumors at 6-month follow-up ( p = 0.01). Solidity variation analysis confirmed that a decrease of tumor solidity at 6-month follow-up was associated with poorer prognosis ( p = 0.01). No association was found between shape features at baseline or shape features at 3-month follow-up with overall survival.

Conclusion

Evolution and variation of tumor morphology during treatment may reflect or correlate with outcomes and contribute toward adapted response criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsImmune Checkpoint InhibitorsTomography, X-Ray ComputedCarcinoma, HepatocellularHumansRetrospective StudiesMaleFemaleMiddle AgedAgedResponse Evaluation Criteria in Solid TumorsTreatment OutcomeFeasibility StudiesAged, 80 and overContrast MediaChemoembolization, Therapeutic

Stichwörter der Autor:innen

Follow-up studiesImmunotherapyLiver neoplasmsResponse evaluation criteria in solid tumorsRetrospective studies

Substanzen

Immune Checkpoint InhibitorsContrast Media

Autor:innen und Institutionen

  • Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. Laetitia.saccenti@nih.gov.
  • Henri Mondor's Institute of Biomedical Research - Inserm, U955 Team No. 18, Créteil, France. Laetitia.saccenti@nih.gov.
  • Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
  • Philips Research of North America, Cambridge, MA, USA.
  • Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer, Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Förderung

  • Société Française de Radiologie
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institutes of Health Clinical Center

Zitieren

APA

Saccenti, L., Varble, N., Borde, T., Mikhail, A. S., Kassin, M., Levy, E., Xu, S., Hazen, L. A., Ukeh, I., Vasco, C., Duffy, A. G., Xie, C., Monge, C., Mabry, D., Greten, T. F., & Wood, B. J. (2024). Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy. La radiologia medica. https://doi.org/10.1007/s11547-024-01937-1

Vancouver

Saccenti L, Varble N, Borde T, Mikhail AS, Kassin M, Levy E, et al. Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy. La radiologia medica. 2024. doi:10.1007/s11547-024-01937-1

BibTeX
@article{Saccenti2024,
  author = {Saccenti, Laetitia and Varble, Nicole and Borde, Tabea and Mikhail, Andrew S and Kassin, Michael and Levy, Elliot and Xu, Sheng and Hazen, Lindsey A and Ukeh, Ifechi and Vasco, Cyndi and Duffy, Austin G and Xie, Changqing and Monge, Cecilia and Mabry, Donna and Greten, Tim F and Wood, Bradford J},
  title = {Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy},
  journal = {La radiologia medica},
  year = {2024},
  doi = {10.1007/s11547-024-01937-1}
}
Kostenlos starten →